Last reviewed · How we verify
Combination Product: Nivolumab with Pemetrexed
Combination Product: Nivolumab with Pemetrexed is a Small molecule drug developed by AHS Cancer Control Alberta. It is currently in Phase 2 development. Also known as: Opdivo (trade name for Nivolumab), Alimta (brand name for Pemetrexed).
At a glance
| Generic name | Combination Product: Nivolumab with Pemetrexed |
|---|---|
| Also known as | Opdivo (trade name for Nivolumab), Alimta (brand name for Pemetrexed) |
| Sponsor | AHS Cancer Control Alberta |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (PHASE3)
- Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (PHASE2)
- First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. (PHASE3)
- DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC (PHASE2)
- A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) (PHASE1, PHASE2)
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (PHASE2)
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination Product: Nivolumab with Pemetrexed CI brief — competitive landscape report
- Combination Product: Nivolumab with Pemetrexed updates RSS · CI watch RSS
- AHS Cancer Control Alberta portfolio CI
Frequently asked questions about Combination Product: Nivolumab with Pemetrexed
What is Combination Product: Nivolumab with Pemetrexed?
Combination Product: Nivolumab with Pemetrexed is a Small molecule drug developed by AHS Cancer Control Alberta.
Who makes Combination Product: Nivolumab with Pemetrexed?
Combination Product: Nivolumab with Pemetrexed is developed by AHS Cancer Control Alberta (see full AHS Cancer Control Alberta pipeline at /company/ahs-cancer-control-alberta).
Is Combination Product: Nivolumab with Pemetrexed also known as anything else?
Combination Product: Nivolumab with Pemetrexed is also known as Opdivo (trade name for Nivolumab), Alimta (brand name for Pemetrexed).
What development phase is Combination Product: Nivolumab with Pemetrexed in?
Combination Product: Nivolumab with Pemetrexed is in Phase 2.
Related
- Manufacturer: AHS Cancer Control Alberta — full pipeline
- Also known as: Opdivo (trade name for Nivolumab), Alimta (brand name for Pemetrexed)
- Compare: Combination Product: Nivolumab with Pemetrexed vs similar drugs
- Pricing: Combination Product: Nivolumab with Pemetrexed cost, discount & access